Table 1.
Patients with ductal and lobular inflammatory breast cancer in the National Cancer Database, 2010–2019
| Ductal | Lobular | All patients | p | ||
|---|---|---|---|---|---|
| n = 10,445 | n = 1456 | N = 11,901 | |||
| Age median (IQR) | 57 (48–66) | 62 (52–71) | 58 (49–67) | < 0.001 | |
| Age | <50 | 2835 (27.1) | 294 (20.2) | 3129 (26.3%) | < 0.001 |
| 50–59 | 3,019 (28.9) | 336 (23.1) | 3,355 (28.2%) | ||
| 60–69 | 2,573 (24.6) | 415 (28.5) | 2,988 (25,1%) | ||
| 70–79 | 1,265 (12.1) | 240 (16.5) | 1,505 (12.6%) | ||
| >80 | 753 (7.2) | 171 (11.7) | 924 (7.8%) | ||
| Race/ethnicity | AI/AN | 43 (0.4) | 10 (0.7) | 53 (0.4%) | < 0.001 |
| Hispanic | 741 (7.1) | 79 (5.4) | 820 (6.9%) | ||
| NH Asian/PI | 305 (2.9) | 25 (1.7) | 330 (2.8%) | ||
| NH black | 2031 (10.4) | 220 (15.1) | 2,251 (18.9%) | ||
| NH white | 7177 (68.7) | 1097 (75.3) | 8274 (69.5%) | ||
| Unknown | 148 (1.4) | 25 (1.7) | 173 (1.5%) | ||
| Subtype | HER2+ | 3604 (34.5) | 369 (25.3) | 3973 (33.4%) | < 0.001 |
| HR+/HER2− | 3646 (34.9) | 805 (55.3) | 4451 (37.4%) | ||
| TNBC | 2566 (24.6) | 195 (13.4) | 2761 (23.2%) | ||
| Unknown | 629 (6.0) | 87 (6.0) | 716 (6.0%) | ||
| Tumor size (cm) | <1 | 346 (3.3) | 36 (2.5) | 382 (3.2%) | < 0.001 |
| 1–1.9 | 860 (8.2) | 115 (7.9) | 975 (8.2%) | ||
| 2–2.9 | 998 (9.6) | 97 (6.7) | 1,095 (9.2%) | ||
| 3–3.9 | 956 (9.2) | 127 (8.7) | 1083 (9.1%) | ||
| 4–4.9 | 873 (8.4) | 86 (5.9) | 959 (8.1%) | ||
| >5 | 6,412 (61.4) | 995 (68.3) | 7407 (62.2%) | ||
| Node-negative | No** | 5895 (56.4) | 798 (54.8) | 6693 (56.2%) | < 0.001 |
| Yes** | 1848 (17.7) | 185 (12.7) | 2033 (17.1%) | ||
| Nodes not examined | 2556 (24.5) | 454 (31.2) | 3010 (25.3%) | ||
| Unknown | 146 (1.4) | 19 (1.3) | 165 (1.4%) | ||
| Lymph node count | No nodes examined | 2556 (24.5) | 454 (31.2) | 3010 (25.3%) | < 0.001 |
| <10 | 2,248 (21.5) | 310 (21.3) | 2,558 (21.5%) | ||
| ≥10 | 3711 (35.5) | 455 (31.3) | 4,166 (35%) | ||
| Unknown | 1930 (18.5) | 237 (16.3) | 2167 (18.2%) | ||
| Types of breast surgery | Modified radical mastectomy | 4230 (40.5%) | 519 (35.6%) | 4749 (39.9%) | 0.002 |
| Total mastectomy | 1768 (16.9%) | 244 (16.8%) | 2012 (16.9%) | ||
| Other surgery | 1,280 (12.3%) | 192 (13.2%) | 1,472 (12.4%) | ||
| None | 3167 (30.3%) | 501 (34.4%) | 3668 (30.8%) | ||
| Guideline-concordant surgery (GCS) vs. other types of surgery | GCS (i.e., MRM and/or TM with ≥10 LN excised) | 4859 (46.5%) | 599 (41.1%) | 5458 (45.9%) | < 0.001 |
| Other surgery | 2,419 (23.2%) | 356 (24.5%) | 2775 (23.3%) | ||
| None | 3167 (30.3%) | 501 (34.4%) | 3668 (30.8%) | ||
| Clinical N classification | cN0 | 1430 (13.7%) | 298 (20.5%) | 1728 (14.5%) | < 0.001 |
| cN1 | 5230 (50.1%) | 684 (47.0%) | 5914 (49.7%) | ||
| cN2 | 1600 (15.3%) | 200 (13.7%) | 1800 (15.1%) | ||
| cN3 | 1903 (18.2%) | 226 (15.5%) | 2129 (17.9%) | ||
| Unknown | 282 (2.7%) | 48 (3.3%) | 330 (2.8%) | ||
| Pathological T classification | pT0 | 1404 (13.50%) | 136 (9.3%) | 1540 (12.9%) | < 0.001 |
| pT1 | 943 (9.0%) | 95 (6.5%) | 1,038 (8.7%) | ||
| pT2 | 796 (7.6%) | 116 (8.0%) | 912 (7.7%) | ||
| pT3 | 595 (5.7%) | 178 (12.2%) | 773 (6.5%) | ||
| pT4 | 1702 (16.3%) | 232 (15.9%) | 1934 (16.3%) | ||
| Other | 5005 (47.9%) | 699 (48.0%) | 5704 (47.9%) | ||
| Pathological N classification | pN0 | 2547 (24.4%) | 272 (18.7%) | 2819 (23.7%) | < 0.001 |
| pN1 | 1684 (16.1%) | 195 (13.4%) | 1879 (15.8%) | ||
| pN2 | 1,303 (12.5%) | 218 (15.0%) | 1,521 (12.8%) | ||
| pN3 | 827 (7.9%) | 151 (10.4%) | 978 (8.2%) | ||
| Other | 4084 (39.1%) | 620 (42.6%) | 4704 (39.5%) | ||
| Received radiation | Administered | 3228 (31.0%) | 478 (32.8%) | 3716 (31.2%) | 0.334 |
| None | 5669 (54.3%) | 777 (53.4%) | 6446 (54.2%) | ||
| Possible inappropriate administration (e.g., whole breast) | 789 (7.6%) | 113 (7.8%) | 902 (7.6%) | ||
| Other | 749 (7.25%) | 88 (6%) | 837 (7%) | ||
| Received endocrine therapy* | < 0.001 | ||||
| Yes | 2786 (76.4%) | 655 (81.4%) | 3441 (77.3%) | ||
| No | 860 (23.6%) | 150 (18.6%) | 1010 (22.7%) | ||
*HR + patients only; N = 4,451
**Lymph nodes removed at surgery and examined by pathologist.
IQR Interquartile range; AI/AN American Indian/Alaska Native; NH Non-Hispanic; TNBC Triple-negative breast cancer; MRM Modified radical mastectomy